Ken Griffin Leap Therapeutics, Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$0.29 - $0.72 $178,446 - $443,039
615,332 Added 142.64%
1,046,712 $355,000
Q4 2022

Feb 14, 2023
BUY
$0.42 - $9.18 $117,753 - $2.57 Million
280,365 Added 185.65%
431,380 $194,000
Q3 2022

Nov 14, 2022
SELL
$0.92 - $9.3 $4,827 - $48,797
-5,247 Reduced 3.36%
151,015 $133,000

Others Institutions Holding LPTX

# of Institutions
1
Shares Held
265K
Call Options Held
0
Put Options Held
0
View Full List

About LEAP THERAPEUTICS, INC.

LPTX Quotes by TradingView
  • Ticker LPTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,021,400
  • Market Cap $254M
  • Description
  • Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...
More about LPTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email